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Telomerase, an enzyme related with cellular immortality, has been extensively studied in many kinds of malignant tumours for clinical
diagnostic or prognostic utilities. Telomerase activity is mainly regulated by the expression of hTERT (human telomerase reverse
transcriptase), which is a catalytic component of human telomerase. To evaluate whether the levels of hTERT mRNA provides a
molecular marker of hepatoblastoma malignancy, we examined hTERT mRNA expression levels in the primary hepatoblastoma
tissues by fluorescent RT–PCR using LightCycler technology and followed up the clinical outcomes in 63 patients listed in the
Japanese Study Group of Pediatric Liver Tumor between 1991 and 2002. The hTERT mRNA expression was detected in 61 (96.8%)
specimens and their expression levels ranged between 0.1/1000 and 745.1/1000 copies of PBGD gene that was used as an internal
control. Among these cases, frozen 39 tumour samples and 14 adjacent noncancerous liver tissues were analysed for semiquantitative
telomerase assay. In the 39 tumour samples, the levels of telomerase activity ranged between 0.11 and 2709 TPG and 12 (30.7%) had
high telomerase activity (4100 TPG), whereas only nine of 14 noncancerous liver tissue samples showed telomerase activity which
was less than 1.0 TPG. The levels of telomerase activity were significantly correlated with the levels of hTERT mRNA expression
(Po0.001). The frequency of high hTERT mRNA expression and/or high telomerase activity did not significantly associate with the
clinicopathological factors except for stage of disease. The prognosis of the patients with high hTERT mRNA expression was
significantly worse than that of others (Po0.01), as was the patients with high telomerase activity (Po0.01). Multivariate analysis
indicated that high levels of hTERT mRNA expression as well as telomerase activity are independent prognosis-predicting factors in
patients with hepatoblastoma.
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Hepatoblastoma is one of the common paediatric tumours and
more than 70% of the tumours are diagnosed in children less than
2 years old (Weinberg and Finegold, 1983). This tumour, which is
derived from hepatic precursor cells, is morphologically similar to
immature hepatocytes and the prognosis of the patients is various.
In the previous reports, tumour distribution, stage of tumour, and
complete tumour resection were proposed to be the prognostic
indicators in hepatoblastoma (Brown et al, 2000; Fuchs et al, 2002).
The prognosis of children with hepatoblastoma has been improved
significantly during the past two decades. Several multicentric
trials such as the International Society of Pediatric Oncology
(SIOP), United States-Intergroup, and our JPLT (the Japanese
Study Group for Pediatric Liver Tumors) group studies, revealed
that the successful reduction of large hepatoblastoma tumours by
preoperative chemotherapy and complete resection are possible in
many patients. In other instances, some tumours grow aggressively
regardless of the use of preoperative chemotherapy. The latter
tumours are considered to have high-grade malignancy. In
advanced tumours with a low malignant grade, standard
chemotherapeutic regimens are effective to reduce the primary
tumour and to diminish metastatic tumours, resulting in patients’
long survival, while new aggressive chemotherapy such as high-
dose chemotherapy with stem cell transplantation is needed to
cure the tumours with a high-grade malignancy (Nishimura et al,
2002). Thus, evaluation of the malignant grade of hepatoblastoma
is necessary to improve the outcome of patients with advanced
hepatoblastoma. Several molecular markers have been analysed to
identify hepatoblastomas with high malignant potential: loss of
heterozygosity (LOH) of chromosome 11p15.5, which is often
affected in nephroblastoma and rhabdomyosarcoma in children,
may contain a putative tumour suppressor gene for hepatoblas-
toma (Albrecht et al, 1994), but is unlikely to be a prognostic
marker (Samuel et al, 1999; von Schweinitz et al, 2002). The
mutation or deletion of the b-catenin gene exon 3 is frequently
detected in hepatoblastoma, suggesting overactivation of the
wingless/WNT signal pathway (Koch et al, 1999). This plays an
important role in the pathogenesis of hepatoblastoma, but is not
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tumours from others (Takayasu et al, 2001; von Schweinitz et al,
2002).
In Japan, JPLT was opened to enrollment in 1991 and more than
150 patients were treated by JPLT protocols (Sasaki et al, 2002).
The event-free survival (EFS) rate of patients with advanced stages
was under 50%. Except for stage of disease, there are few markers
to predict the prognosis of patients or to evaluate the malignant
grade of hepatoblastoma. Elucidation of the useful prognosis-
predicting factors is necessary to improve the prognosis of patients
with hepatoblastoma.
Telomeres, which are specialised structures containing unique
guanine-rich hexameric repeat sequences at the ends of human
chromosomes (Blackburn, 1991), cannot be completely synthe-
sised (referred to as the end-replication problem) with each cell
division (Watson, 1972) and it is proposed that the loss of telomere
eventually induces antiproliferative signals that result in cellular
senescence (Shay, 1995). Telomerase is activated to maintain
telomere length to compensate for the end-replication problem in
germlines and immortal cells, but repressed in almost all human
somatic cells. The activation of telomerase and the stabilisation of
telomeres appear to be concomitant with the attainment of
immortality in cancer cells (Harley et al, 1994; Kim et al, 1994;
Shay, 1995). Telomerase activity has been found in approximately
85% of the cancer tissues examined, covering a large variety of
cancer types including neuroblastoma, Wilms’ tumour, and
retinoblastoma (Hiyama et al, 1995a; Gupta et al, 1996; Dome
et al, 1999; Hiyama and Hiyama, 2002). In some kinds of tumours,
in which telomerase activity increases according to tumour
progression, such as in neuroblastoma, non-small lung carcinoma,
and colorectal cancer, the level of telomerase activity is a useful
prognostic marker of the patients (Tatsumoto et al, 2000; Hiyama
and Hiyama, 2002, 2003). Major components of telomerase are the
RNA template (human telomerase RNA component: hTR) and the
catalytic subunit (human telomerase reverse transcriptase:
hTERT). hTR is expressed in the tissues with or without telomerase
activity and is not correlated with the detection of telomerase
activity, while hTERT expression is correlated with the detection of
telomerase activity (Naito et al, 2001; Hiyama and Hiyama, 2002).
Although hTERT transcripts show several splicing variants which
have no telomerase activity (Wick et al, 1999), a system to detect
full-length-hTERT mRNA alone has been developed.
To evaluate whether the levels of hTERT mRNA provides a
molecular marker of hepatoblastoma malignancy, in the present
study, we examined hTERT mRNA expression with this system and
telomerase activity in hepatoblastoma specimens and compared
the levels of their expression and the clinicopathological features
and outcomes of the patients.
MATERIALS AND METHODS
Tissue samples
Hepatoblastoma tissue samples were obtained at surgery,
immediately frozen, and stored at  801C in the Tissue Bank of
the JPLT or in the Hiroshima University Medical Hospital. In
all, 63 tumours having total RNA samples available were enrolled
in this study. The patients with these tumours were treated in
the various hospitals or institutes under the framework of the
JPLT between 1991 and 2001. Most patients were treated in
the JPLT-1 study (Sasaki et al, 2002), which consisted of
two different protocols: protocol 91A for patients with stage I
or II hepatoblastoma and protocol 91B for patients with stage III
or IV tumours. In these cases, 39 tumour samples with
14 corresponding normal liver tissues were stored at  801Ca s
frozen tissues and the remaining 24 samples were stored as total
RNA samples.
Clinical course and disease status
The clinicopathological parameters and outcomes for these 63
patients were analysed. The clinical stages of disease were
determined at the time of initial biopsy or resection according to
the classification of the Japanese Society of Pediatric Surgeons,
which was based on the number of liver segments involved, the
extent of local invasion, the extent of regional lymph node
involvement, and the presence of distant metastases (Hata, 1990).
The PRETEXT system (intrahepatic tumour extension) is based on
hepatic surgical anatomy which is divided into four sectors,
namely anterior and posterior sectors on the right and medial and
lateral sectors on the left (Brown et al, 2000). Histological subtypes
were diagnosed according to the classification of Haas et al and the
Japanese Society of Pathology (Haas et al, 1989; Hata, 1990). Their
criteria classified the tumours into four subtypes: a well-
differentiated (fetal), a poorly differentiated (embryonal), imma-
ture (anaplastic) and other (including macrotrabecular pattern)
types.
Quantification of telomerase activity
Extraction of telomerase protein and evaluation of its activity were
done by the TRAP (telomeric repeat amplification protocol) assay
as described earlier (Kim et al, 1994; Piatyszek et al, 1995). Briefly,
50–100mg of tumour or noncancerous liver tissues were
homogenised in approximately 50–100ml of CHAPS lysis buffer.
After 25min of incubation on ice, the lysates were centrifuged at
16000g for 20min at 41C and the supernatant was rapidly frozen
in liquid nitrogen and stored at  801C. An aliquot of extract
containing 0.5mg of protein was used for each assay. The levels of
telomerase activity was measured using a commercial kit, the
TRAPeze XL kit (Serological Co., Gaithersburg, MD, USA), which
is a quantitative fluorescent-labelled PCR system for the estimation
of relative telomerase activity with the use of a PCR internal
control. The PCR product was measured in the fluorescent plate
reader (Wallac, Perkin-Elmer, Wellesley, MA, USA) to detect the
levels of fluorescein and sulphorhodamine by using the appro-
priate excitation and emission filters. The levels of telomerase
activity were quantified by the ratio of the fluorescein intensity of
the entire TRAP ladder to the sulphorhodamine intensity of the
internal control after the correction of each fluorescent intensity
for the negative control and the background, respectively, and
were expressed as Total Product Generated (TPG) units.
Quantification of hTERT mRNA expression
Using the acid-guanidium-phenol-chloroform method (Chrom-
zynski and Sacchi, 1987), total cellular RNA was extracted.
Quantitative detection of hTERT mRNA was performed with the
LightCycler TeloTAGGG hTERT Quantification Kit (Roche Diag-
nostics, Mannheim, Germany) using the LightCycler instrument
(Roche Molecular Systems, Alameda, CA, USA). For each sample,
100ng of total RNA was prepared in a 20ml mixture containing 2ml
of reaction mix, 0.1ml of reverse-transcriptase, and 2ml of hTERT
or porphobilinogen deaminase (PBGD) detection mix. RT–PCR
for the mRNA encoding the housekeeping gene PBGD was equally
processed in a separate tube as a reference for relative quantifica-
tion of hTERT mRNA expression. The mixture without template
was examined as the negative control. These mixtures were
reverse-transcribed for 10min at 601C, followed by denaturation
(30s at 951C) and amplification of the 198-bp fragment of the
hTERT mRNA sequence in 40 PCR cycles (0.5s at 951C, 10s at
601C, and 10s at 721C) using specific primers in a one-step RT–
PCR. To establish a standard curve, five standards with in vitro-
transcribed hTERT mRNA containing five different copy numbers
were included in each experiment. The copy number of hTERT
mRNA in each sample was normalised on the basis of its PBGD
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sion level¼hTERT mRNA copies/1000 PBGD mRNA copies.
Statistical analysis
Correlations between the hTERT mRNA expression and telomerase
activity levels or each of the other factors were analysed using
Wilcoxon’s t-test, w
2-test, or Fisher’s exact test where appropriate.
The overall survival curves for each group of patients were
estimated by the Kaplan–Meier method and the resulting curves
were compared using the Cox–Mantel test. Multivariate survival
analysis using the Cox proportional hazard regression model was
carried out to assess the independent contribution of each variable
to disease-free survival. Differences were considered significant at
Po0.05. A Computer program package (StatView 5.0; Abacus
Concepts, Berkeley, CA, USA) was used for all of the statistical
testing.
RESULTS
Clinicopathological findings (Table 1)
Among the 63 patients studied, the ages at diagnosis ranged
between 0 and 13 years (mean 3 years and 6 months). They
included nine stage I cases, 17 stage II, 13 stage IIIA, 10 stage IIIB,
and 14 stage IV cases. Overall, 39 (61.9%) cases underwent curative
surgery. Surgical resection was considered curative when no
distant metastasis was evident and the clearance of cancer was
complete as determined by standard histological analysis. The
remaining 24 cases underwent noncurative surgery due to distant
metastasis or extensive occupation of primary tumour. Totally, 34
cases underwent preoperative chemotherapy and all cases under-
went postoperative chemotherapy.
In histological classification according to the pathological
criteria of the Japanese Society of Pathology, 33 were classified
as the well-differentiated type, 27 as the poorly differentiated type,
two as immature and the remaining one case as other types. Serum
levels of alpha-fetoprotein (AFP) ranged between 5 and
3657247ngml
 1 and 56 cases showed more than 1000ngml
 1 of
AFP.
Among these patients, 11 died of disease, two showed recurrence
of tumour and 50 are alive disease free. The survival periods
ranged from 0 to 288 months (mean 74 months).
Out of 39 cases whose frozen tumour samples were available
included six stage I cases, 13 stage II, five stage IIIA, eight stage
IIIB, and seven stage IV cases. Among them 30 (75.9%) cases
underwent curative surgery. Clinicopathological findings in these
39 cases were not significantly different from those in the whole
cases (Table 1).
Levels of hTERT mRNA expression and telomerase activity
in hepatoblastoma specimens
Among the 63 primary hepatoblastoma specimens obtained, 58
(92%) specimens displayed apparent hTERT mRNA expression
using the quantitative hTERT mRNA expression assay (Figure 1A–
C). The levels of hTERT mRNA expression ranged from 0.008 to
745.1 (mean 49.5) copies1000 copies
 1 of the PBDG mRNA. In
these 58 cases, 24 (38.1%) showed high levels of hTERT mRNA
expression (more than 10 hTERT mRNA copies1000 copies
 1 of
the PBDG mRNA). In the 14 noncancerous liver specimens
examined, only two samples derived from two patients under 1-
year old showed hTERT mRNA expression, but their levels were
low (0.42 and 0.78). Among these cases, telomerase activity was
examined in 39 cases. Using quantitative TRAP assay (Figure 1D),
telomerase activity ranged between 0.11 and 2669 TPG (mean 432.7
TPG). As previously described (Tatsumoto et al, 2000), more than
100 TPG was defined as high telomerase activity. Overall, 12 cases
(30.8%) showed high telomerase activity. Figure 1E shows the
correlation between hTERT mRNA expression levels and telomer-
ase activity levels. There was a significant correlation between
these two expression levels (g ¼0.87, Po0.01).
Levels of hTERT mRNA expression or telomerase activity
and the clinicopathological features of the patients
Table 1 shows the correlation between hTERT mRNA expression
or telomerase activity levels and the clinicopathological features of
the patients. Regarding age at diagnosis, the levels of hTERT
mRNA expression and of telomerase activity were high in the elder
patients, but not significantly. In histological classification, there
was no significant difference of the levels of hTERT mRNA
expression or telomerase activity between well- and poorly
differentiated types. In PRETEXT classification, the levels of
hTERT mRNA expression increased in PRETEXT 2, 3, and 4
tumours but not significantly (P¼0.116). The levels of telomerase
activity in the PRETEXT 2, 3, and 4 tumours were significantly
higher than in the PRETEXT 1 tumours (P¼0.025). The levels of
hTERT mRNA expression and telomerase activity significantly
increased in advanced stages (stages IIIA, IIIB, and IV, P¼0.0146
Table 1 Patients and tumour characteristics
(Cases)
hTERT
mRNA
(copies) (Cases)
Telomerase
activity
(TPG)
Sex
Male 44 61.747130.94 27 445.87792.5
Female 19 37.48790.80 12 403.47809.6
Age
0–11 months 12 27.28762.94 7 458.17990.0
12–23 months 18 57.85797.72 12 722.371214.3
2–3 years 20 21.14748.34 10 122.87269.1
4–14 years 13 130.327210.93 10 687.57689.8
PRETEXT
I 6 2.5674.88 5 101.57207.3
II 22 56.027160.07 15 184.47514.1
III 20 62.84790.01 8 624.47998.1
IV 11 65.557106.82 9 579.771045.6
Unknown 4 25.76750.09 2 630.17890.6
Stage
I 9 1.8374.03 6 86.47189.0
II 17 17.49746.34 13 174.17545.8
IIIA 13 39.63761.47 5 333.17706.7
IIIB 10 105.507134.93 8 915.071072.0
IV 14 104.417197.70 7 729.97969.6
Histology
Well 33 58.637138.63 20 574.57878.2
Poorly 27 51.21796.00 17 312.87704.3
Others 3 3.5773.37 2 34.178.37
Preoperative chemotherapy
Yes 34 63.617149.14 19 486.67802.7
No 29 40.18765.60 20 381.67789.7
Curative surgery
Yes 39 56.917130.29 30 397.47758.8
No 24 46.19796.98 9 550.37914.6
Prognosis
Survived with
evidence-free
50 33.25772.11 30 252.77604.2
Recurrence/died of
disease
13 128.117207.25 9 1032.871046.0
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Figure 1 Detection of hTERT mRNA (A, B) and telomerase activity (C, D) and their relationship (E, F) in hepatoblastoma. (A) Amount of hTERT mRNA
was measured by real-time RT–PCR analysis using LightCycler system in three representative hepatoblastoma samples (LB8, 21, and 25) with five external
hTERT mRNA standards (a–e) and a negative control (f). (B) hTERT mRNA levels of three representative samples were calculated by the standard curve of
the external hTERT RNA standards (a–e). (C) Detection of telomerase activity was done using the TRAPeze XL kit (Serological Co., Gaithersburg, MD,
USA), which is a quantitative fluorescence-labelled PCR system for the estimation of relative telomerase activity with the use of a PCR internal control (IS).
Positive controls included serial diluted control template (R8), oligonucleotides with eight telomeric repeats AG(GGTTAG)7, to produce a standard curve.
(D) The levels of telomerase activity were quantified by the ratio of the fluorescein intensity (DFL) of the entire TRAP ladder to the sulphorhodamine
intensity (DR) of the internal control, and were expressed as Total Product Generated units (TPG). Levels of telomerase activity in the three representative
samples (LB8, 21, and 25) were calculated by the standard curve using DFL/DR of the external standard R8. The levels of telomerase activity in LB8, LB21,
and LB25 were calculated as 31.1, 0.37, and 761.7 TPG, respectively. (E, F) The correlation between the levels of hTERT mRNA expression normalised to
the internal control PBDG and those of telomerase activity in overall 39 hepatoblastoma samples (E) and those with low telomerase activity (F). There is a
significant correlation between these two parameters (Po0.0001).
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(stage IV vs others), but not significantly. The levels of hTERT
mRNA expression (mean 49.9, n¼22) and telomerase activity
(mean 369.1 TPG, n¼14) in tumours obtained after preoperative
chemotherapy did not significantly differ from those in tumours
obtained without any therapies (mean 54.4, n¼42 and mean 435.4,
TPG, n¼25, respectively). There was no significant correlation
between the levels of serum AFP and hTERT mRNA expression or
telomerase activity.
Correlation between hTERT mRNA expression and
prognosis of the patients
The median follow-up in the series of patients examined was 74
months (range, 1–288 months). Kaplan–Meier event-free survival
(EFS) curves of all patients (Figure 2A) show that the 10-year EFS
rate in the patients with high hTERT mRNA expression (X10
copies1000 copies
 1 of the PBDG gene) was 38%, while that in the
remaining patients was approximately 90%. The prognosis of the
patients with high expression of hTERT was significantly worse
than that of other patients (w
2¼23.40, Po0.0001). Since the levels
of hTERT mRNA were significantly correlated with advanced
stages of tumour, the correlation between hTERT mRNA expres-
sion and prognosis was examined in tumours in early stages (stage
I or II), and those in advanced stages (stage III or IV), separately
(Figure 2B). The prognosis of the patients with high levels of
hTERT mRNA expression was significantly poor in advanced
tumours (w
2¼26.03, Po0.0001). In 26 patients with early tumours,
all 20 patients with low levels of hTERT mRNA expression are alive
disease free and two out of six patients with high levels of hTERT
mRNA expression showed poor prognosis (w
2¼3.291, P¼0.046).
Correlation between the levels of telomerase activity and
prognosis of the patients
This study attempted to determine the effect of telomerase activity
and hTERT mRNA expression on the prognosis of patients with
hepatoblastoma. Telomerase activity was investigated in only 39
cases because frozen tumour tissue was unavailable in the
remaining 24 cases. Kaplan–Meier EFS curves of these 39 patients
(Figure 2C) show that the 10-year EFS rate in the patients with high
telomerase activity (TPG X100) was approximately 40%, while
that in the remaining patients was approximately 90%. The
prognosis of the patients with high telomerase activity (TPG
X100) was significantly worse than that of other patients
(P¼0.0003). Since the levels of telomerase activity were signifi-
cantly correlated with advanced stages of tumour, the correlation
between telomerase activity and prognosis was examined in the
tumours in early stages (stage I or II) and those in advanced stages
(stage III or IV), separately (Figure 2D). The prognosis of the
patients with high telomerase activity was significantly poor in
advanced tumours (w
2¼27.12, Po0.0001). In early tumours, one
of two patients with high telomerase activity showed poor
prognosis, while all patients with low telomerase activity are alive
disease free.
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Figure 2 Kaplan–Meier cumulative survival spots for patients with hepatoblastoma. (A) Survival according to the levels of hTERT mRNA expression. High
hTERT: hTERT mRNA X10 copies1000 copies
 1 of the PBDG genes, low hTERT: hTERT mRNA o10 copies1000 copies
 1 of the PBDG genes. The patients
with tumours with high hTERT mRNA expression showed significantly worse survival (Po0.0001). (B) Survival according to the levels of hTERT mRNA
expression and stages. Early stages: I and II, advanced stages: III and IV in the stage classification of the Japanese Society of Pediatric Surgeons. Patients having
advanced tumours with high hTERT mRNA expression showed significantly worse survival (Po0.0001). (C) Survival according to the levels of telomerase
activity. High telomerase: TPG value X100, low telomerase: TPG value o100. The patients having tumours with high telomerase activity showed
significantly worse survival (Po0.0001). (D) Survival according to the levels of telomerase activity and stages. The patients having advanced tumours with
high telomerase activity showed significantly worse survival (Po0.0001).
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By univariate analysis, we analysed clinical parameters such as
PRETEXT classification, distant metastasis, stage classification,
serum levels of AFP, histological classification, preoperative
chemotherapy, and total surgical resection, for the correlation
with prognosis of the patients. PRETEXT 2, 3, and 4 tumours and
the tumours with distant metastasis showed poorer prognosis, but
not significantly. On the other hand, advanced stages (stages 3 and
4) were significantly correlated with poor prognosis of the patients
(P¼0.022). Thus, both telomerase activation and advanced stages
were correlated with poor prognosis of patients.
To identify which independent factors had a significant
influence on survival, multivariate survival analysis using the
Cox proportional hazard regression model was performed. In this
multivariate analysis, we assessed the prognostic value for event-
free survival of the parameters that were significant in univariate
analysis: stage and hTERT mRNA expression. For this multivariate
analysis, variables with P-value lower than 0.30 in the univariate
analysis were also selected: gender, age at diagnosis, curative
surgery, stage/PRETEXT classification, histology, and hTERT/
telomerase activity. As stage classification was significantly
associated with PRETEXT and distant metastasis, we used stage
classification in this multivariate analysis. As the levels of hTERT
mRNA expression were significantly correlated with the levels of
telomerase activity, and telomerase activity could not be analysed
in 24 cases, we analysed these two factors separately in different
multivariate analysis sheets. In the multivariate analysis including
hTERT mRNA expression and the other five factors for 63 cases,
hTERT mRNA and poorly differentiated histology were indepen-
dent predictors of EFS. The hazard ratios were 50.0 (95%
confidence interval of 5.07 492.9, P¼0.0008) and 5.11 (95%
confidence interval of 1.16 22.5, P¼0.031). In the multivariate
analysis including telomerase activity and the other five factors for
39 cases, the level of telomerase activity was also an independent
predictor of EFS. The hazard ratio of telomerase activity levels was
17.7 (95% confidence interval of 2.16 120.1, P¼0.0032). In
advanced stages, the hazard ratios for hTERT mRNA and
telomerase activity levels were 9.221 (P¼0.043) and 5.248
(P¼0.188), respectively.
DISCUSSION
Clinical investigation revealed that the prognosis of children with
hepatoblastoma correlates with multifocal growth in the liver,
invasion of blood vessels, distant metastasis, and either very low or
high levels of serum AFP (von Schweinitz et al, 1997; Brown et al,
2000). Survival rates of children with more than two of these
factors were less than 10%. Thus, these findings discriminate a
subgroup of hepatoblastoma with more aggressive biological
properties, which correlate with a poor prognosis. However, these
factors are not sufficient to predict the prognosis of children with
hepatoblastoma. Recently, high-dose chemotherapy with stem cell
transplantation has become effective in some patients with
aggressive hepatoblastoma with metastasis (Nishimura et al,
2002). Thus, to identify such high-risk patients with hepatoblas-
toma, we need additional useful prognostic markers for evaluation
of aggressive biological properties.
Telomerase activity has been reported in many kinds of
malignant tumours, including gastric cancer (Hiyama et al,
1995b), hepatocellular carcinoma (Nouso et al, 1996; Nakashio
et al, 1997), pancreatic cancer (Hiyama et al, 1997b; Iwao et al,
1997), and colorectal cancer (Chadeneau et al, 1995; Naito et al,
2001). Approximately 80–90% of these malignant tumours showed
telomerase activity (Shay and Bacchetti, 1997). In some kinds of
tumours, high telomerase activity has been reported as a marker of
tumour aggressiveness and poor prognosis (Hiyama et al, 1995a,b;
Shay et al, 1997; Marchetti et al, 1999). In childhood tumours,
telomerase activity and hTERT mRNA expression were also
detected in a majority of cases of neuroblastoma, retinoblastoma,
and nephroblastoma. In neuroblastoma, we have already reported
a significant correlation between high telomerase activity and poor
outcomes of patients (Hiyama et al, 1995a, 1997a). In retinoblas-
toma, telomerase activity was detected in about 50% of the
tumours and such tumours showed a high recurrence rate (Gupta
et al, 1996). In the present study, hTERT mRNA expression and
telomerase activity were correlated with poor prognosis of
patients, indicating these factors are useful prognosis-predicting
factors in hepatoblastoma. Thus, activation of telomerase may
correlate with malignant potential in most childhood malignant
tumours including hepatoblastoma, neuroblastoma, and retino-
blastoma.
This is the first report to show an association between the levels
of hTERT mRNA expression or telomerase activity and patient
prognosis in hepatoblastoma. In the multivariate analysis, activa-
tion of telomerase, stage of disease, and histological type were
significantly correlated with the outcome of patients. In these three
independent parameters, the risk of hTERT mRNA or telomerase
activation was highest, indicating that telomerase reactivation is
the most useful prognosis-associating factor in hepatoblastoma. In
the present study, four (15.4%) of the 26 cases with early stage
hepatoblastoma showed recurrence of tumours, and all four cases
showed high telomerase activity (TPG X100 or hTERT mRNA
X100copies). In contrast, three (16.7%) of the 18 advanced cases
with high telomerase activity remain disease-free. Since all stage 4
cases underwent different chemotherapeutic regimen in the JPLT
study (Sasaki et al, 2002), one explanation for this result is that the
high-dose chemotherapy might have been effective in preventing
recurrence in these four early cases. Thus, in early stage tumours,
selection of patients for high-dose chemotherapy based on high
telomerase activity (TPG X100) might be an effective method to
improve the prognosis of this category of patient. Moreover, the
exclusion of low-risk patients from postoperative chemotherapy
could spare some of its serious side effects. In advanced
hepatoblastoma with low malignancy, complete resection and
chemotherapy should be performed, but in such tumours with
high malignancy, complete resection and chemotherapy might be
insufficient and new aggressive strategies should be implemented.
The observations in our study suggest that telomerase inhibition is
an effective strategy for the reversal of tumour growth. Since most
somatic cells do not have detectable telomerase activity and
telomerase shows a tumour-specific expression in general,
telomerase is an important target for new anticancer therapy. A
number of different approaches have been developed for
telomerase inhibition in human cancer. Different components
and type of inhibitors targeting various regulatory levels have
been regarded as useful telomerase inhibitors and seem to be
most efficient when combined with conventional chemotherapy
(Saretzki, 2003). Telomerase inhibition, which may be involved in
triggering apoptosis, may be a new strategy for curing hepato-
blastoma in the future.
In the present study, we analysed the clinical variables of
hepatoblastoma cases, but did not find significant correlation
between the levels of hTERT mRNA or telomerase activity and
these variables except for PRETEXT system and disease-stage. It is
well-known that prognosis of the cases with pure-foetal histology
is good (Finegold, 2002). In the present study, we had only two
pure-foetal subtypes in 33 well-differentiated tumours. Although
the levels of hTERT mRNA or telomerase activity in them were
relatively low, further study with large number of this subtype is
necessary to analyse statistically.
Some noncancerous childhood liver tissues showed low levels of
telomerase activity and hTERT mRNA expression. In childhood
liver tissue infiltrating lymphocytes, multipotential stem cells, and
their daughter cells might have telomerase activity, resulting in
positive results by the contamination of lymphocytes and stem
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telomere maintenance by the existence of telomerase activity is
necessary for the proliferation of normal human cells (Masutomi
et al, 2003). Thus, low levels of telomerase activity may reflect the
proliferation of normal hepatocytes in children. To solve this false-
positive problem, in situ evaluation is necessary to analyse the
origin of telomerase expression in clinical samples using hTERT
mRNA ISH (Chou et al, 2001; Kumaki et al, 2001; Kotoula et al,
2002) or hTERT immunohistochemistry (Yasui et al, 1999; Hiyama
et al, 2001).
In summary, we show that an increased level of hTERT
mRNA expression or telomerase activity is a prognostic indicator
of poor outcome in patients with hepatoblastoma, independent
of disease stage and histological classification. Although it would
need large series to clarify the correlation between clinical
variables and the levels of hTERT mRNA or telomerase
activity, high telomerase activity may stratify patients that
are likely to have cancer recurrence requiring postoperative
aggressive chemoadjuvant therapy, or, in the future, telomerase-
targeting therapy.
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